The Globe and Mail
Bookmark
Please log in to listen to this story. Also available in French and Mandarin. Log In Create Free Account
Getting audio file ...
This translation has been automatically generated and has not been verified for accuracy. Full Disclaimer
Geoff Robins/The Globe and Mail
A tiny London, Ont., medical device company hoping to change how diabetes is treated has had a wild ride of late. Last Friday, stock in Sernova Corp. shot up 65 per cent on the TSX Venture Exchange, then nearly doubled on Monday, closing at $2.42 a share. At its peak, Sernova had a market capitalization of $630-million, making it one of Canada’s 15 most valuable publicly traded life sciences companies.